These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 29285224)

  • 1. Soluble chemokine (C-X-C motif) ligand 16 (CXCL16) in urine as a novel biomarker candidate to identify high grade and muscle invasive urothelial carcinomas.
    Lang K; Bonberg N; Robens S; Behrens T; Hovanec J; Deix T; Braun K; Roghmann F; Noldus J; Harth V; Jöckel KH; Erbel R; Tam YC; Tannapfel A; Käfferlein HU; Brüning T
    Oncotarget; 2017 Dec; 8(62):104946-104959. PubMed ID: 29285224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TGFBI Protein Is Increased in the Urine of Patients with High-Grade Urothelial Carcinomas, and Promotes Cell Proliferation and Migration.
    Lang K; Kahveci S; Bonberg N; Wichert K; Behrens T; Hovanec J; Roghmann F; Noldus J; Tam YC; Tannapfel A; Käfferlein HU; Brüning T
    Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31514337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The chemokine receptor CXCR6 and its ligand CXCL16 are expressed in carcinomas and inhibit proliferation.
    Meijer J; Ogink J; Kreike B; Nuyten D; de Visser KE; Roos E
    Cancer Res; 2008 Jun; 68(12):4701-8. PubMed ID: 18559516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between CXCL16/CXCR6 expression and the clinicopathological features of patients with non-small cell lung cancer.
    Ke C; Ren Y; Lv L; Hu W; Zhou W
    Oncol Lett; 2017 Jun; 13(6):4661-4668. PubMed ID: 28599467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microsatellite analysis of voided-urine samples for surveillance of low-grade non-muscle-invasive urothelial carcinoma: feasibility and clinical utility in a prospective multicenter study (Cost-Effectiveness of Follow-Up of Urinary Bladder Cancer trial [CEFUB]).
    van der Aa MN; Zwarthoff EC; Steyerberg EW; Boogaard MW; Nijsen Y; van der Keur KA; van Exsel AJ; Kirkels WJ; Bangma C; van der Kwast TH
    Eur Urol; 2009 Mar; 55(3):659-67. PubMed ID: 18501499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prognostic significance of CXCL16 and its receptor C-X-C chemokine receptor 6 in prostate cancer.
    Richardsen E; Ness N; Melbø-Jørgensen C; Johannesen C; Grindstad T; Nordbakken C; Al-Saad S; Andersen S; Dønnem T; Nordby Y; Bremnes RM; Busund LT
    Am J Pathol; 2015 Oct; 185(10):2722-30. PubMed ID: 26272362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CXCR6/CXCL16 functions as a regulator in metastasis and progression of cancer.
    Deng L; Chen N; Li Y; Zheng H; Lei Q
    Biochim Biophys Acta; 2010 Aug; 1806(1):42-9. PubMed ID: 20122997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methylomics analysis identifies ZNF671 as an epigenetically repressed novel tumor suppressor and a potential non-invasive biomarker for the detection of urothelial carcinoma.
    Yeh CM; Chen PC; Hsieh HY; Jou YC; Lin CT; Tsai MH; Huang WY; Wang YT; Lin RI; Chen SS; Tung CL; Wu SF; Chang DC; Shen CH; Hsu CD; Chan MW
    Oncotarget; 2015 Oct; 6(30):29555-72. PubMed ID: 26320192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Site-directed mutagenesis of the chemokine receptor CXCR6 suggests a novel paradigm for interactions with the ligand CXCL16.
    Petit SJ; Chayen NE; Pease JE
    Eur J Immunol; 2008 Aug; 38(8):2337-50. PubMed ID: 18629940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Associations of CXCL16/CXCR6 with carotid atherosclerosis in patients with metabolic syndrome.
    Lv Y; Hou X; Ti Y; Bu P
    Clin Nutr; 2013 Oct; 32(5):849-54. PubMed ID: 23398954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression and potential function of the CXC chemokine CXCL16 in pancreatic ductal adenocarcinoma.
    Wente MN; Gaida MM; Mayer C; Michalski CW; Haag N; Giese T; Felix K; Bergmann F; Giese NA; Friess H
    Int J Oncol; 2008 Aug; 33(2):297-308. PubMed ID: 18636150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CXCR6 expression in non-small cell lung carcinoma supports metastatic process via modulating metalloproteinases.
    Mir H; Singh R; Kloecker GH; Lillard JW; Singh S
    Oncotarget; 2015 Apr; 6(12):9985-98. PubMed ID: 25888629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluble CXCL16 and risk of myocardial infarction: The HUNT study in Norway.
    Laugsand LE; Åsvold BO; Vatten LJ; Janszky I; Platou C; Michelsen AE; Arain F; Damås JK; Aukrust P; Ueland T
    Atherosclerosis; 2016 Jan; 244():188-94. PubMed ID: 26649903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decreased plasma CXCL16/SR-PSOX concentration is associated with coronary artery disease.
    Sheikine Y; Bang CS; Nilsson L; Samnegård A; Hamsten A; Jonasson L; Eriksson P; Sirsjö A
    Atherosclerosis; 2006 Oct; 188(2):462-6. PubMed ID: 16378611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell surface-anchored SR-PSOX/CXC chemokine ligand 16 mediates firm adhesion of CXC chemokine receptor 6-expressing cells.
    Shimaoka T; Nakayama T; Fukumoto N; Kume N; Takahashi S; Yamaguchi J; Minami M; Hayashida K; Kita T; Ohsumi J; Yoshie O; Yonehara S
    J Leukoc Biol; 2004 Feb; 75(2):267-74. PubMed ID: 14634054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Muscle-invasive bladder cancer is characterized by overexpression of thymidine kinase 1.
    Rausch S; Hennenlotter J; Teepe K; Kuehs U; Aufderklamm S; Bier S; Mischinger J; Gakis G; Stenzl A; Schwentner C; Todenhöfer T
    Urol Oncol; 2015 Oct; 33(10):426.e21-9. PubMed ID: 26231311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CXCL16/SR-PSOX is an interferon-gamma-regulated chemokine and scavenger receptor expressed in atherosclerotic lesions.
    Wuttge DM; Zhou X; Sheikine Y; Wågsäter D; Stemme V; Hedin U; Stemme S; Hansson GK; Sirsjö A
    Arterioscler Thromb Vasc Biol; 2004 Apr; 24(4):750-5. PubMed ID: 14988089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced 5-methylcytosine level as a potential progression predictor in patients with T1 or non-invasive urothelial carcinoma.
    Chung CJ; Chang CH; Chuu CP; Yang CR; Chang YH; Huang CP; Chen WC; Chung MC; Chang H
    Int J Mol Sci; 2014 Dec; 16(1):677-90. PubMed ID: 25561224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of the CXCL16/CXCR6 Pathway by Inflammation Contributes to Atherosclerosis in Patients with End-stage Renal Disease.
    Hu ZB; Chen Y; Gong YX; Gao M; Zhang Y; Wang GH; Tang RN; Liu H; Liu BC; Ma KL
    Int J Med Sci; 2016; 13(11):858-867. PubMed ID: 27877078
    [No Abstract]   [Full Text] [Related]  

  • 20. The use of urinary nuclear matrix protein 22 (NMP22) as a diagnostic adjunct to urine cytology for monitoring of recurrent bladder cancer--institutional experience and review.
    Önal B; Han Ü; Yilmaz S; Köybasioglu F; Altuğ U
    Diagn Cytopathol; 2015 Apr; 43(4):307-14. PubMed ID: 25488052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.